rss
Sex Transm Infect doi:10.1136/sti.2006.022335

Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK.

  1. S Tariq Sadiq (ssadiq{at}sgul.ac.uk)
  1. St George's, University of London, United Kingdom
    1. M R Pakianathan (mark.pakianathan{at}stgeorges.nhs.uk)
    1. St George's Healthcare NHS Trust, United Kingdom
      • Published Online First 10 November 2006

      Abstract

      The hypersensitivity reaction (HSR) associated with the antiretroviral abacavir does not usually have serious outcomes unless recognised late or following re-challenge. Pharmacogenetic testing of HLA B*5701 (B*5701) for HSR risk is being used increasingly in clinical practice backed by strong evidence among Caucasians and Hispanics1. In the Western Australian landmark studies, updated to improve diagnostic accuracy, positive and negative predictive values (PPV and NPV) of B*5701 for HSR were 78.9% and 99.4%1 respectively. When B*5701 screening was introduced into this cohort2, and in Brighton UK3, no HSR were observed in 148 and 185 B*5701 negative patients respectively treated with abacavir.

      This Article

      1. Abstract
      2. PDF
      3. All versions of this article:
        1. sti.2006.022335v1
        2. 83/3/181most recent

      Responses

      1. Submit a response
      2. No responses published

      Register for free content

      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.